Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.49 |
| ▸ | PIM1 | P11309 | 5/20 | 0.49 |
| ▸ | CDC7 | O00311 | 5/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.49 |
| ▸ | CDK2 | P24941 | 4/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.49 |
| ▸ | CDK8 | P49336 | 3/20 | 0.49 |
| ▸ | CLK2 | P49760 | 3/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.49 |
| ▸ | HIPK4 | Q8NE63 | 3/20 | 0.49 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.49 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339497 | 0.92 | GSK3B (0.45) | GSK3BPIM1CDC7AURKBCDK2 | |
| SCHEMBL13305018 | 0.91 | DYRK1A (0.40) | GSK3BPIM1CDC7AURKBCDK2 | |
| SCHEMBL3342410 | 0.86 | CDC7 (0.41) | GSK3BPIM1CDC7AURKBCDK2 | |
| SCHEMBL3338698 | 0.86 | MAPK1 (0.41) | GSK3BPIM1CDC7AURKBCDK2 | |
| SCHEMBL14080581 | 0.85 | CDC7 (0.34) | GSK3BPIM1CDC7AURKBCDK2 | |
| SCHEMBL3338699 | 0.84 | PIM1 (0.36) | GSK3BPIM1CDC7AURKBCDK2 | |
| SCHEMBL3340028 | 0.83 | CDC7 (0.45) | GSK3BPIM1CDC7AURKBCDK2 | |
| SCHEMBL3337518 | 0.83 | CDC7 (0.40) | GSK3BPIM1CDC7AURKBCDK2 | |
| SCHEMBL14080580 | 0.83 | MAPK1 (0.36) | GSK3BPIM1CDC7AURKBCDK2 | |
| SCHEMBL3341849 | 0.83 | CDC7 (0.40) | GSK3BPIM1CDC7AURKBCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074114-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | claimed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | claimed |
| EP-2074114-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008143759-A1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK2A2, CSNK1A1 | GSK3B 422/4885PIM1 579/4885CDC7 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.